InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.515 0.01 (1.90%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$140 Application for quotation of securities - OCC 3 Mar 2025 5:21PM $1.315 $0.515 fallen by 60.84%
$140 Application for quotation of securities - OCC 28 Feb 2025 2:39PM $1.295 $0.515 fallen by 60.23%
$140 Orthocell Webinar Presentation 26 Feb 2025 9:07AM $1.245 $0.515 fallen by 58.63%
$140 Orthocell Webinar 25 Feb 2025 9:53AM $1.315 $0.515 fallen by 60.84%
$140 Appendix 4D & Half-Year Financial Report 24 Feb 2025 5:03PM $1.315 $0.515 fallen by 60.84%
$140 Remplir FDA Application submitted for US$84M Thai Market 21 Feb 2025 8:55AM $1.460 $0.515 fallen by 64.73%
$140 Cleansing Notice 18 Feb 2025 5:25PM $1.615 $0.515 fallen by 68.11%
$140 Application for quotation of securities - OCC 18 Feb 2025 5:22PM $1.615 $0.515 fallen by 68.11%
$140 Remplir Regulatory Application Submitted for Canada 3 Feb 2025 9:00AM $1.570 $0.515 fallen by 67.20%
$140 Strong Sales Drives Acceleration of Remplir Global Expansion 22 Jan 2025 8:58AM $1.300 $0.515 fallen by 60.38%
$140 Orthocell Receives $3.18 million R&D Tax Refund 20 Jan 2025 8:58AM $1.370 $0.515 fallen by 62.41%
$140 Quarterly Activity Report & Appendix 4C 15 Jan 2025 9:10AM $1.310 $0.515 fallen by 60.69%
$140 Notification regarding unquoted securities - OCC 14 Jan 2025 3:55PM $1.315 $0.515 fallen by 60.84%
$140 Application for quotation of securities - OCC 14 Jan 2025 3:07PM $1.350 $0.515 fallen by 61.85%
$140 Application for quotation of securities - OCC 14 Jan 2025 3:00PM $1.350 $0.515 fallen by 61.85%
$140 Option Terms and Conditions 14 Jan 2025 11:03AM $1.365 $0.515 fallen by 62.27%
$140 Proposed issue of securities - OCC 14 Jan 2025 10:59AM $1.360 $0.515 fallen by 62.13%
$140 Third Consecutive Quarter of Record Revenue for Orthocell 8 Jan 2025 9:03AM $1.255 $0.515 fallen by 58.96%
$140 US FDA Application Submitted for Remplir as US Launch Nears 19 Dec 2024 9:02AM $1.255 $0.515 fallen by 58.96%
$140 Major Milestone with First Sales of Remplir in Singapore 12 Dec 2024 9:02AM $1.000 $0.515 fallen by 48.50%
$140 Application for quotation of securities - OCC 10 Dec 2024 6:59PM $0.960 $0.515 fallen by 46.35%
$140 Cleansing Notice 3 Dec 2024 6:09PM $0.880 $0.515 fallen by 41.48%
$140 Change of Director's Interest Notice-John Van Der Wielen 3 Dec 2024 5:58PM $0.880 $0.515 fallen by 41.48%
$140 Application for quotation of securities - OCC 3 Dec 2024 5:55PM $0.880 $0.515 fallen by 41.48%
$140 Notification regarding unquoted securities - OCC 3 Dec 2024 1:33PM $0.870 $0.515 fallen by 40.80%

151 - 175 of 775 results

Page 7 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.